Structure Therapeutics Inc. has announced its financial results for the first quarter of 2025. The company reported a net loss of $46.8 million for the quarter, compared to a net loss of $26.0 million in the same period of 2024. This increase in net loss is associated with higher research and development expenses, which rose to $42.9 million from $20.7 million in the previous year. The rise in R&D expenses is attributed to increased preclinical research and development costs, clinical trial costs, and personnel-related expenses due to headcount expansion. General and administrative expenses also increased to $13.4 million from $11.3 million in the same period of 2024, primarily due to personnel-related expenses as the company expanded its infrastructure. Structure Therapeutics highlighted its strong financial position with cash, cash equivalents, and short-term investments totaling $836.9 million, which are expected to support projected operations and key clinical milestones through at least 2027. The company is progressing with its Phase 2b ACCESS and ACCESS II studies for aleniglipron, with data anticipated by the end of 2025. Additionally, the initiation of a Phase 1 study for its oral small molecule amylin receptor agonist, ACCG-2671, is expected by the year-end. These developments aim to expand patient access and options for treating obesity and related diseases.